Superpower peptides available for pre-order. Get first access.
Not FDA-approved
Brain & sleep
What are the side effects of semax?
Semax side effects: see what FDA's adverse-event database, clinical use in Russia, and animal studies report, plus product checks and when to call a clinician.
Quick answer
Semax is not FDA-approved. Its safety record comes from clinical use in Russia, nasal studies, and animal research. FDA's 2026 review found one adverse-event report through December 3, 2025: eye pain and burning after nasal drops, with a hospitalization. Published human studies all used nasal doses, and FDA found no safety data for injected Semax. Any new symptom warrants a call to the prescribing clinician. Wheezing or facial swelling, with or without hives, needs emergency care.
- Published
- November 4, 2026
- Last updated
- November 4, 2026
What Semax side effects have been reported?
FDA's adverse-event database held one Semax report through December 3, 2025. It described eye pain and burning after nasal drops1.
In May 2024, a consumer had those symptoms after using Semax 0.1% nasal drops bought online1. The consumer reported a hospitalization, and the eye pain had not resolved by the May 2025 report. FDA's literature searches found no published human case reports1 of adverse events. Reports like these help identify concerns, but they do not show how often an effect occurs.
What do studies show about Semax safety?
Most Semax safety information comes from clinical use in Russia, published nasal studies, and animal research. Semax is registered as nasal drops in Russia1. Its developers' review of clinical use reported no negative side effects or complications2. That record is one reason Semax is often described as well tolerated.
FDA's 2026 review found too little clinical information to characterize1 its safety profile. Most human studies FDA reviewed did not discuss adverse events1. The published human studies all used nasal doses, and FDA found no safety data for injected Semax1.
| Group studied | People in the studies |
| Healthy adults | 33 to 47 |
| Adults with medical conditions | 69 |
| Children with depression, tics, or Tourette syndrome | 4511 |
N-acetyl Semax, a modified variant, has different chemical and biological properties3. Its data do not describe Semax.
What concerns has FDA raised from Semax animal data?
FDA noted two Semax safety concerns from animal studies: a possible bleeding risk and amplified stimulant effects1.
In rats, Semax showed anticoagulant and antithrombotic (anti-clotting) effects. FDA raised concern for people prone to bleeding1 or taking drugs that raise bleeding risk. In mice, Semax boosted amphetamine-induced dopamine release1 in a reward-related brain region. FDA found no studies of Semax abuse potential.
FDA also did not identify acute, repeat-dose, reproductive, or adequate carcinogenicity1 studies of Semax. The product a person receives is part of the safety picture too.
Semax product quality and safety
Compounded drugs are not FDA-approved, and FDA does not verify their quality4 before sale.
- Purity: FDA found neither Semax free base nor Semax acetate well characterized1.
- Sterility testing: The quality certificates FDA reviewed for Semax acetate1 lacked endotoxin (bacterial toxin) and bioburden (microbe) tests.
- Immune reactions: Clumped peptide and impurities may pose an immune-reaction risk5 for injected and nasal Semax, and FDA found no clinical immunogenicity studies1.
- Storage and delivery: FDA reports Semax free base stable when stored below -4°F (-20°C)1 and flags concerns about nasal-spray containers and pumps.
A new symptom can stem from the Semax peptide, the product, or the route.
How can Semax side effects be managed?
Any new symptom after Semax is worth a call to the prescribing clinician. Signs of a severe allergic reaction call for emergency care right away6.
- Write it down: Timing, product, and route help the prescribing clinician judge a symptom, including eye or nose discomfort.
- Contact the prescribing clinician: Frequent nosebleeds warrant a provider visit7.
- Report a reaction: Compounders generally do not report adverse events1 to FDA, so patients can report one to FDA's MedWatch program8.
- Get emergency care: Wheezing or facial swelling, with or without hives, can develop within minutes6 and need 911. So does a nosebleed lasting over 20 minutes or during blood-thinner use7.
Personal bleeding risk is worth reviewing with the prescribing clinician before a first Semax dose.
Getting Semax in 2026
Superpower will offer Semax formulated in FDA-registered facilities in the US, backed by third-party lab testing, and distributed from US-licensed pharmacies. A licensed clinician will review each person's health history to decide whether Semax fits their health care. The Superpower peptide waitlist is open now.
Semax is not an FDA-approved drug. The Department of Health and Human Services announced in October 2026 that it does not intend to take enforcement action9 against state-licensed pharmacies compounding a group of peptides while the 503A Bulks List, which names the ingredients pharmacies may use in compounding, is finalized. The interim policy covers six peptides in all, Semax among them10, on conditions including FDA-registered ingredient sources and a patient-specific prescription. The announcement followed a July 2026 FDA advisory committee recommendation that Semax join the list11, and rulemaking is ongoing.